AGN.AS (Aegon Ltd.) — Execution Log

Position Summary

Pre-Buy Red Flag Check (2026-03-06)

Fresh data was pulled on the day of purchase. Key findings:

GREEN (thesis intact)

• Dividend: raised 11% to EUR 0.40/yr. >5% growth guidance reiterated for 2026-2027. Yield 6.9% at entry.
• Buyback: EUR 400M program confirmed for 2026. 25% cumulative share count reduction since 2021.
• Solvency: 184% group solvency ratio — healthy, well above regulatory minimums.
• Short interest: ~0.1% of float — negligible.
• FY2025 operating result: EUR 1.7B, up 15% YoY. OCG EUR 1.3B, exceeded EUR 1.2B target.

AMBER (watch closely)

• Earnings quality: FY2025 beat partly supported by one-offs. H2 net result EUR 375M vs EUR 741M prior year (-49%), driven by non-operating charges. Underlying was in-line, not a genuine beat.
• EPS revisions post-earnings: 2025 EPS cut -29.7% (backward-looking IFRS reconciliation), 2026 forward cut only -1.9% (minor).
• UBS downgrade to Neutral (Dec 2025): cited limited upside on sum-of-parts, high market/credit exposure. Low analyst target EUR 6.30 is close to entry price.
• US redomicile: Moving legal domicile to Delaware, rebranding as Transamerica by Jan 2028. Introduces multi-year execution risk (IFRS→US GAAP transition, shareholder vote Q4 2026, $800M capital injection into Transamerica, reduced reporting cadence from 2026).
• Insider data gap: Could not verify insider buying/selling for current period from available sources.
• WFG margin pressure: World Financial Group profitability squeezed by compliance/tech investments despite strong sales.

No EXIT triggers hit

None of the fundamental stops (dividend cut, buyback cancelled, solvency breach) were triggered.

Entry Rationale

Aegon is a post-transformation European insurer trading at crisis-level multiples (forward P/E ~6x) despite successfully restructuring. The market prices in negative growth (-0.2% implied) for a company actively shrinking its share count by ~7%/year. Aggressive capital return (buybacks + dividends = ~15% total yield) should force a re-rating over 2-3 years.

Graham screen score 6/7 — strongest in the STOXX 600 quick screen. Margin of safety 82.7%. Composite qualitative score 4.0/5.

Exit Plan

Profit targets (sell in thirds)

Fundamental stops (no price-based stop losses)

• EXIT: Dividend cut, buyback cancelled, solvency ratio breach
• RE-SCORE: UK sale falls through, two consecutive earnings misses
• TRIM: Qualitative score drops below 3/5

Time horizon

• Re-score every semi-annual earnings
• Exit if no progress by September 2027 (18 months)

Watchlist Alerts

• AGN.AS-TP1 — above EUR 8.50
• AGN.AS-TP2 — above EUR 10.50
• AGN.AS-TP3 — above EUR 14.50

Monitoring Calendar

• Next earnings: H1 2026 results (~Aug 2026) — re-score all 5 qualitative factors
• UK business sale: Track for completion/failure (RE-SCORE trigger)
• US redomicile vote: Q4 2026 shareholder meeting
• Buyback execution: Track share count quarterly

Related Files

• Thesis: output/graham/scores/AGN_AS_thesis.md
• Plan (structured): output/graham/scores/AGN_AS_plan.json
• Qualitative scores: output/graham/scores/AGN_AS.json
• Research data: output/research/stocks/AGN/agn_research.md